391: Rituximab Infusion after Allogeneic HCT Prevents Donor B Cell Reconstitution and Alloimmunity One Year Post Transplant

Sahaf, B.; Chen, G.; Boiko, Julie R.; Heydari, Kartoosh; Arai, Satoko; Miklos, D.

doi:10.1016/j.bbmt.2007.12.401

Cited by 3 publications

(2 citation statements)

References 0 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…(94) Thus, rituximab treatment post allogeneic HCT may potentially eliminate CD20+ alloreactive cells while leaving early pre and pro B cells to develop into nonalloreactive mature B cells. Rituximab therapy is well tolerated with relatively few infectious complications (91) because long-lived host plasma cells continue to secrete protective antimicrobial antibodies (95). …”

Section: Rationale For Rituximab Treatment Of Chronic Gvhdmentioning

confidence: 99%

B Cells and Transplantation: An Educational Resource

Small

Robinson

Miklos

2009

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Section: Rationale For Rituximab Treatment Of Chronic Gvhdmentioning

confidence: 99%

B Cells and Transplantation: An Educational Resource

Small

Robinson

Miklos

2009

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

“…However, use of rituximab posttransplantation risks delaying recovery of a donor-derived B cell immune response. Rituximab therapy 2 months after allo-HSCT prevents donor B cell reconstitution up to 1 year after transplantation [69,70]. The half-life of rituximab, despite the influence of the tumor burden, could range from several days to months.…”

Section: Time To Explore Preventive Strategies For Bos After Hsctmentioning

confidence: 99%

Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Sengsayadeth

Srivastava

Jagasia

et al. 2012

Biology of Blood and Marrow Transplantation

View full text Add to dashboard Cite

Although allogeneic hematopoietic stem cell transplant (allo-HSCT) is performed to treat otherwise incurable and fatal diseases, transplantation itself can lead to life-threatening complications due to organ damage. Pulmonary complications remain a significant barrier to the success of allo-HSCT. Lung injury, a frequent complication after allo-HSCT, and noninfectious pulmonary deaths account for a significant proportion of non-relapse mortality. Bronchiolitis obliterans syndrome (BOS) is a common and potentially devastating complication. BOS is now considered a diagnostic criterion of chronic graft-versus-host-disease (cGVHD), and National Institutes of Health (NIH) consensus has been published to establish guidelines for diagnosis and monitoring of BOS. It usually occurs within the first 2 years but may develop as late as 5 years after transplantation. Recent prevalence estimates suggest that BOS is likely underdiagnosed, and when severe BOS does occur, current treatments have been largely ineffective. Prevention and effective novel approaches remain the primary tools in the clinician's arsenal in managing BOS. This article provides an overview of the currently available and novel strategies for BOS, and we also discuss specific preventive interventions to reduce severe BOS after allo-HSCT. Therapeutic trials continue to be needed for this orphan disease.

show abstract

Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

Reddy

Rezvani

Barrett

et al. 2011

Biology of Blood and Marrow Transplantation

106

View full text Add to dashboard Cite

Epstein-Barr virus (EBV)-associated postallogeneic stem cell transplantation (SCT) lymphoproliferative disorder (PTLD) is often life threatening. The risk of EBV reactivation is highest in older patients, T cell-depleted SCT (in vivo or vitro), and in unrelated or mismatched SCT. Cumulative numbers of patients with EBV reactivation and PTLD are rising as more patients at high risk for EBV reactivation and PTLD are receiving allo-SCT. Novel but easily applicable strategies are needed to prevent EBV reactivation and PTLD to serve the needs of the increasingly enlarging population of high-risk SCT recipients across the globe.

show abstract

391: Rituximab Infusion after Allogeneic HCT Prevents Donor B Cell Reconstitution and Alloimmunity One Year Post Transplant

Cited by 3 publications

References 0 publications

B Cells and Transplantation: An Educational Resource

B Cells and Transplantation: An Educational Resource

Time to Explore Preventive and Novel Therapies for Bronchiolitis Obliterans Syndrome after Allogeneic Hematopoietic Stem Cell Transplantation

Strategies to Prevent EBV Reactivation and Posttransplant Lymphoproliferative Disorders (PTLD) after Allogeneic Stem Cell Transplantation in High-Risk Patients

Contact Info

Product

Resources

About